Oxidative Stress In Stargardt Disease, Age Related Macular Degeneration and Diabetic Retinopathy
NCT ID: NCT02875704
Last Updated: 2022-09-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
77 participants
OBSERVATIONAL
2017-01-03
2022-09-22
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety and Efficacy of Anti-Oxidants and Anti-inflammatory Agents in Glaucoma and Diabetic Retinopathy
NCT02984813
Oxidative Stress in Patients With Age-Related Macular Degeneration
NCT00465400
Natural History, Pathogenesis, and Outcome of Ocular Disorders
NCT02821767
Effect of DHA Supplements on Macular Function in Patients With Stargardt Macular Dystrophy and Stargardt-like Macular Dystrophy
NCT00060749
Macular Pigment and Visual Performance in Glaucoma Patients
NCT03959592
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Stargardt disease, AMD, DR patients
Stargardt disease, Age Related Macular Degeneration, Diabetic Retinopathy patients
Anterior Chamber (AC) Tap
Aqueous Samples will be collected for measurement of biomarkers
Controls
Patients without retinal disease who will be undergoing cataract surgery
Anterior Chamber (AC) Tap
Aqueous Samples will be collected for measurement of biomarkers
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Anterior Chamber (AC) Tap
Aqueous Samples will be collected for measurement of biomarkers
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age at least 18 years
* For the study group, patients diagnosed with Stargardt disease, age related macular degeneration and diabetic retinopathy by the investigators, based on clinical phenotype
* For the control group, patients with no retinal disease undergoing cataract surgery will be eligible.
Exclusion Criteria
18 Years
100 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Johns Hopkins University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Peter A Campochiaro, MD
Role: PRINCIPAL_INVESTIGATOR
Johns Hopkins University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Wilmer Eye Institute
Baltimore, Maryland, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
OXI-SAD
Identifier Type: OTHER
Identifier Source: secondary_id
IRB00112564
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.